By Gregory Laub
September 4, 2026
The landscape of metabolic medicine has been irrevocably altered by the arrival of glucagon-like peptide-1 (GLP-1) receptor agonists. Drugs like semaglutide and tirzepatide have demonstrated an unprecedented ability to reduce body weight and mitigate cardiometabolic risk, sparking a global frenzy in both the pharmaceutical market and public discourse. Yet, as these medications dominate headlines, a growing chorus of public health experts warns that we are mistaking a therapeutic advancement for a societal solution.
According to Laura Schmidt, PhD, of the University of California San Francisco, the "Ozempic era" risks creating a dangerous blind spot. While these drugs are potent tools for clinical intervention, they do not address the environmental catalysts driving the global obesity epidemic. In a new perspective piece published in Science, Schmidt and co-author Luc Hagenaars, PhD, of Amsterdam University Medical Center, argue that if we treat obesity solely as a medical pathology to be "cured" by pharmacy, we are destined to fail at curbing its systemic roots.
The Mirage of the "Magic Bullet"
For decades, the medical community has grappled with the complexity of obesity. The temptation to reach for a pharmacological solution is powerful, as it offers a quantifiable, individual-focused intervention for a condition that has historically been difficult to manage. However, Schmidt argues that this narrative mirrors past public health failures.
"They’re not a magic bullet," Schmidt stated in an exclusive interview with MedPage Today. "We have a history of looking to medications as the magic bullet for problems that are fundamentally systemic. By defining obesity purely as a medical condition requiring pharmaceutical treatment, we are taking our eyes off the ball regarding the food environment—the true driver of the problem."
The central concern is that the medicalization of obesity shifts the burden of proof and responsibility away from the structural environment and onto the individual. When the solution is a pill, the underlying reality of the modern "obesogenic" environment—characterized by the pervasive availability of ultraprocessed foods—remains unaddressed.
Chronology of a Crisis: From Individual Choice to Structural Failure
To understand the current impasse, one must look at how the medical and public health communities have historically framed obesity.
- 1990s–2000s: The "Personal Responsibility" Era. Public health messaging largely focused on "calories in, calories out," emphasizing exercise and willpower. This approach largely failed to halt rising BMI trends.
- 2010s: The Systems Analysis Shift. Researchers began identifying the "food environment" as the primary culprit. Studies showed that the prevalence of ultraprocessed foods—chemically engineered to be hyper-palatable—correlated directly with rising obesity rates.
- 2021–2023: The GLP-1 Breakthrough. The clinical success of semaglutide and similar agents shifted the narrative back to medicalization. As stock prices for pharmaceutical giants soared, the discussion moved away from food policy and toward insurance coverage and drug access.
- 2024–2026: The Current Tension. As the drugs become standard of care, public health experts are pushing back, advocating for a "dual-track" approach: clinical treatment for those already ill, and regulatory reform to prevent the next generation from falling into the same trap.
The Evidence: Why Ultraprocessed Foods Are the Primary Driver
The scientific consensus has shifted significantly regarding what drives metabolic dysfunction. Schmidt points to extensive systems analyses, including her own work with Hagenaars, which confirm that ultraprocessed foods are not merely "unhealthy" in a vague sense—they are biologically disruptive.
"We know from clinical trials that ultraprocessed foods cause obesity," Schmidt explains. "They induce overeating and force the body to consume more calories than a diet based on unprocessed, whole foods. If that is the mechanical driver of the epidemic, then focusing exclusively on medicalizing the outcome is moving in the wrong direction."
The issue is not simply one of caloric density; it is one of industrial design. Ultraprocessed foods are formulated to bypass satiety signals, essentially "hacking" the human hunger response. When the environment is saturated with these products, relying on an individual to make "better choices" is structurally flawed.
The Risk of Exacerbating Global Health Disparities
A major concern raised by Schmidt is the geopolitical distribution of these new therapies. If the global response to obesity is purely pharmaceutical, the disparity between high-income and low-income nations will widen.
"If we repeat history—where pharmaceutical companies exert pressure on international bodies like the World Health Organization to prioritize drug distribution—we are going to see these medications flow primarily to high-income countries," Schmidt warns. "This will exacerbate existing health inequities, leaving lower-income populations, who are often the hardest hit by the food environment, without the resources or the policy protections they need."
The commercialization of GLP-1s is already showing signs of this trend. With food companies, pharmaceutical firms, and supplement manufacturers all vying for a piece of the market, the narrative is being shaped by those with a financial stake in the "treatment" model rather than the "prevention" model.
Official Responses and the WHO Agenda
The World Health Organization (WHO) finds itself in a precarious position. While it acknowledges the efficacy of GLP-1 receptor agonists in treating existing cardiometabolic disease, it must balance this with the urgent need for structural reform.
According to Schmidt, the WHO is beginning to recognize the necessity of a bifurcated strategy. "They are saying we need to think about equitable distribution of these medications, but they are also acknowledging that we can have it all," she notes. "We can provide GLP-1s to people already suffering from disease, while simultaneously enacting food environment reforms to prevent the emergence of new cases."
The WHO’s traditional playbook for chronic disease—modeled on the success of tobacco regulation—is the recommended template. This includes:
- Taxation: Implementing excise taxes on sugar-sweetened beverages and ultraprocessed snacks.
- Warning Labels: Clear, front-of-package labeling to inform consumers of the nutritional reality of processed goods.
- Marketing Curbs: Restricting the advertising of unhealthy foods, especially those targeted at children.
- School-Based Interventions: Creating "safe zones" in educational environments where children are protected from the marketing and availability of ultraprocessed products.
The Path Forward: Guardrails for the GLP-1 Era
The "Ozempic era" does not have to be a failure of public health, but it requires guardrails. The pharmaceutical industry is currently driving the narrative, but policymakers must reclaim the agenda.
"Tobacco-style regulations work," Schmidt emphasizes. "We have decades of data showing that when you tax harmful products, put warning labels on them, and curb their marketing, consumption drops. We are dealing with products that use many of the same development and marketing approaches as tobacco. It should come as no surprise that the regulatory solutions are identical."
The challenge lies in the "commercial milieu." In an economy where obesity treatment is projected to be a multi-hundred-billion-dollar industry, the pressure to maintain the status quo is immense. Food companies have a vested interest in the continued consumption of ultraprocessed foods, and pharmaceutical companies have a vested interest in a high-demand, chronic-treatment model.
Conclusion: A Balanced Future
The promise of GLP-1 receptor agonists is real. For millions of people struggling with obesity, these drugs represent a life-changing intervention that can reduce the risk of heart disease, stroke, and diabetes. However, to view them as the only solution is a fundamental miscalculation of human biology and environmental sociology.
As we look toward the future, the policy agenda must shift from a purely clinical focus to a broader, systems-based approach. Treatment and prevention are not mutually exclusive; they are complementary components of a healthy society. By coupling the clinical efficacy of GLP-1s with the regulatory courage to transform our food environment, we can finally stop managing the symptoms of the obesity epidemic and start addressing its cause.
The "Ozempic era" provides us with a unique opportunity: it has focused the world’s attention on the crisis of metabolic health. Now, it is up to policymakers to ensure that this focus translates into meaningful, structural change that lasts long after the medications have left the headlines.
